Targeting IRF7 to overcome gemcitabine resistance in pancreatic ductal adenocarcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) often exhibits resistance to gemcitabine (GEM) chemotherapy.
• Interferon regulatory factor 7 (IRF7) is a key transcription factor in interferon signaling pathways.

Purpose of the Study:

• To elucidate the role of IRF7 in mediating GEM resistance in PDAC.
• To explore therapeutic strategies targeting the IRF7 pathway to enhance GEM efficacy.

Main Methods:

• Analysis of IRF7 expression in GEM-refractory PDAC tissues.
• In vitro functional assays assessing PDAC cell proliferation and apoptosis.
• In vivo studies evaluating tumor growth inhibition with combined treatments.
• Mechanistic investigations into IRF7-mediated gene transcription and immune cell recruitment.

Main Results:

• Elevated IRF7 expression correlates with GEM resistance in PDAC.
• IRF7 enhances PDAC cell proliferation and inhibits apoptosis, contributing to GEM resistance.
• IRF7 activates CCL5 transcription, promoting glycolytic reprogramming and M2 macrophage recruitment, further reinforcing resistance.
• Combined treatment with GEM and temozolomide (TMZ) synergistically reduced tumor progression by suppressing IRF7 activity.

Conclusions:

• IRF7 is a critical regulator of chemotherapy response in PDAC.
• Targeting the IRF7-CCL5 axis with TMZ in combination with GEM demonstrates significant therapeutic potential for overcoming GEM resistance.